Abstract:Background and objectives: Myelin oligodendrocyte glycoprotein antibody-associated disorder (MOGAD) is a rare, autoimmune demyelinating CNS disorder, distinct from multiple sclerosis and neuromyelitis optica spectrum disorder. Characterized by pathogenic immunoglobulin G (IgG) antibodies against MOG, a potential treatment strategy for MOGAD is to reduce circulating IgG levels, e.g., by interference with the IgG recycling pathway mediated by the neonatal Fc receptor (FcRn). Although the optic nerve is often detrimentally involved in MOGAD, the effect of FcRn blockade on the visual pathway has not been assessed. Our objective was to investigate effects of a monoclonal anti-FcRn antibody in murine MOG-IgG-associated experimental autoimmune encephalomyelitis (EAE). Methods: We induced active MOG35-55 EAE in C57Bl/6 mice followed by the application of a monoclonal MOG-IgG (8-18C5) 10 days postimmunization (dpi). Animals were treated with either a specific monoclonal antibody against FcRn (α-FcRn, 4470) or an isotype-matched control IgG on 7, 10, and 13 dpi. Neurologic disability was scored daily on a 10-point scale. Visual acuity was assessed by optomotor reflex. Histopathologic hallmarks of disease were assessed in the spinal cord, optic nerve, and retina. Immune cell infiltration was visualized by immunohistochemistry, demyelination by Luxol fast blue staining and complement deposition and number of retinal ganglion cells by immunofluorescence. Results: In MOG-IgG-augmented MOG35-55 EAE, anti-FcRn treatment significantly attenuated neurologic disability over the course of disease (mean area under the curve and 95% confidence intervals (CIs): α-FcRn [n = 27], 46.02 [37.89-54.15]; isotype IgG [n = 24], 66.75 [59.54-73.96], 3 independent experiments), correlating with reduced amounts of demyelination and macrophage infiltration into the spinal cord. T- and B-cell infiltration and complement deposition remained unchanged. Compared with isotype, anti-FcRn treatment prevented reduction of visual acuity over the course of disease (median cycles/degree and interquartile range: α-FcRn [n = 16], 0.50 [0.48-0.55] to 0.50 [0.48-0.58]; isotype IgG [n = 17], 0.50 [0.49-0.54] to 0.45 [0.39-0.51]). Discussion: We show preserved optomotor response and ameliorated course of disease after anti-FcRn treatment in an experimental model using a monoclonal MOG-IgG to mimic MOGAD. Selectively targeting FcRn might represent a promising therapeutic approach in MOGAD.

Turncoat antibodies unmasked in a model of autoimmune demyelination: from biology to therapy

Soluble MOG35-55/I-Ab Dimers Ameliorate Experimental Autoimmune Encephalomyelitis by Reducing Encephalitogenic T Cells

Analysis of the Cellular Mechanism Underlying Inhibition of EAE after Treatment with Anti-Nkg2a F(ab′)2

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Manipulation of Qa‐1‐restricted CD8 Suppressor Cell Activity in Experimental Autoimmune Encephalomyelitis

A Spontaneous Model of Experimental Autoimmune Encephalomyelitis Provides Evidence of MOG-Specific B Cell Recruitment and Clonal Expansion

Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more

A B Cell-Driven Autoimmune Pathway Leading to Pathological Hallmarks of Progressive Multiple Sclerosis in the Marmoset Experimental Autoimmune Encephalomyelitis Model

Antigen-specific modulation of chronic experimental autoimmune encephalomyelitis in humanized mice by TCR-like antibody targeting autoreactive T-cell epitope

Targeting transmembrane-domain-less MOG expression to platelets prevents disease development in experimental autoimmune encephalomyelitis

Mechanisms of Antigen-Induced Reversal of CNS Inflammation in Experimental Demyelinating Disease.

Antigen-Specific modulation of Chronic Experimental Autoimmune Encephalomyelitis in Humanized Mice by TCR-like Antibody Targeting Auto-Reactive T-Cell Epitope

Specific and Polyfunctional T Cell Response Against N-Methyl-D-aspartate Receptor in an Autoantibody-Mediated Encephalitis Model

Establishment of Murine Experimental Autoimmune Encephalomyelitis Model and Study of the Immunologic Mechanisms

Combination of Apoptotic T Cell Induction and Self-Peptide Administration for Therapy of Experimental Autoimmune Encephalomyelitis

Oligodendrocyte-derived Extracellular Vesicles As Antigen-Specific Therapy for Autoimmune Neuroinflammation in Mice.

Antineonatal Fc Receptor Antibody Treatment Ameliorates MOG-IgG-Associated Experimental Autoimmune Encephalomyelitis

Selective Depletion of Antigen-Specific Antibodies for the Treatment of Demyelinating Disease

Abrogation of Endogenous Glycolipid Antigen Presentation on Myelin-Laden Macrophages by D-Sphingosine Ameliorates the Pathogenesis of Experimental Autoimmune Encephalomyelitis.

Using EAE to better understand principles of immune function and autoimmune pathology

A Comparative Analysis of B Cell-Mediated Myelin Oligodendrocyte Glycoprotein-Experimental Autoimmune Encephalomyelitis Pathogenesis in B Cell-Deficient Mice Reveals an Effect on Demyelination